Literature DB >> 10768961

Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents.

Q Zhang1, S Choo, J Everard, R Jennings, A Finn.   

Abstract

Previous studies in children have shown that Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccines can reduce nasopharyngeal carriage of H. influenzae and provide herd immunity and suggest that this effect is mediated through mucosal antibodies. As this phenomenon may operate in other invasive bacterial infections which are propagated by nasopharyngeal carriage, mucosal antibody responses to meningococcal C conjugate and A/C polysaccharide vaccines were investigated. A total of 106 school children aged 11 to 17 years were randomized to receive a single dose of either conjugate or polysaccharide vaccine in an observer-blind study. Before and at 1, 6, and 12 months after immunization, samples of unstimulated saliva were collected and assayed by enzyme-linked immunosorbent assay for group C polysaccharide-specific immunoglobulin A (IgA), IgA1, IgA2 and secretory component, IgG antibodies, and total IgG and IgA. A subset of serum samples were also assayed for specific IgA and IgG antibodies. The concentrations of specific IgA and IgG in saliva were expressed both as nanograms per milliliter and as nanograms per microgram of total IgA or IgG. One month after immunization, significant increases in antibody titers (both IgA and IgG) were observed in saliva in both groups. There were significant subsequent falls in antibody titers by 6 months. Anti-meningococcal C-specific secretory component and IgA antibody titers were closely correlated (r = 0.85, P < 0.001), but there was no significant correlation between salivary and serum IgA titers, suggesting that IgA antibodies are locally produced. Significant correlation was found between salivary and serum IgG titers (r = 0.52, P < 0.01), suggesting that salivary IgG may be serum derived. Compared with polysaccharide vaccine, the conjugate vaccine induced significantly higher salivary IgG responses (P < 0.05), although there were no significant differences between salivary IgA responses to the two vaccines. The conjugate vaccine induced greater salivary IgG responses than a polysaccharide vaccine. Both vaccines induced significant salivary IgA antibodies. Further studies are needed to establish the functional significance of these mucosal responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768961      PMCID: PMC97476          DOI: 10.1128/IAI.68.5.2692-2697.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

Authors:  J Eskola; H Käyhty; A K Takala; H Peltola; P R Rönnberg; E Kela; E Pekkanen; P H McVerry; P H Mäkelä
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

2.  The Cerebro-Spinal Fever Epidemic of 1917 at X Depôt.

Authors:  J A Glover
Journal:  J Hyg (Lond)       Date:  1918-07

Review 3.  IgA subclasses.

Authors:  J Mestecky; M W Russell
Journal:  Monogr Allergy       Date:  1986

4.  A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.

Authors:  P A Twumasi; S Kumah; A Leach; T J O'Dempsey; S J Ceesay; J Todd; C V Broome; G M Carlone; L B Pais; P K Holder
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

5.  Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children.

Authors:  A K Takala; M Santosham; J Almeido-Hill; M Wolff; W Newcomer; R Reid; H Käyhty; E Esko; P H Mäkelä
Journal:  Pediatr Infect Dis J       Date:  1993-07       Impact factor: 2.129

6.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

7.  Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay.

Authors:  G M Carlone; C E Frasch; G R Siber; S Quataert; L L Gheesling; S H Turner; B D Plikaytis; L O Helsel; W E DeWitt; W F Bibb
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

8.  Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats.

Authors:  M Kauppi; L Saarinen; H Käyhty
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

9.  Parenteral influenza vaccination induces a rapid systemic and local immune response.

Authors:  K A Brokstad; R J Cox; J Olofsson; R Jonsson; L R Haaheim
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

10.  Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.

Authors:  W J King; N E MacDonald; G Wells; J Huang; U Allen; F Chan; W Ferris; F Diaz-Mitoma; F Ashton
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

View more
  20 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  Mucosal and Cellular Immune Responses to Norwalk Virus.

Authors:  Sasirekha Ramani; Frederick H Neill; Antone R Opekun; Mark A Gilger; David Y Graham; Mary K Estes; Robert L Atmar
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

4.  Co-colonization by Haemophilus influenzae with Streptococcus pneumoniae enhances pneumococcal-specific antibody response in young children.

Authors:  Qingfu Xu; Michael E Pichichero
Journal:  Vaccine       Date:  2013-12-16       Impact factor: 3.641

5.  Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.

Authors:  Q Zhang; R Lakshman; R Burkinshaw; S Choo; J Everard; S Akhtar; A Finn
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

Review 7.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children.

Authors:  Qibo Zhang; Sharon Choo; Adam Finn
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 9.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

10.  Antibody in middle ear fluid of children originates predominantly from sera and nasopharyngeal secretions.

Authors:  Ravinder Kaur; Thomas Kim; Janet R Casey; Michael E Pichichero
Journal:  Clin Vaccine Immunol       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.